Stock 6838 FORMOSA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Formosa Pharmaceuticals, Inc.

Equities

6838

TW0006838006

Pharmaceuticals

End-of-day quote Taipei Exchange
Other stock markets
 06:00:00 2024-05-14 pm EDT 		5-day change 1st Jan Change
53.3 TWD 0.00% Intraday chart for Formosa Pharmaceuticals, Inc. +1.33% +6.71%
May. 09 Formosa Pharmaceuticals Announces Licensing Agreement with Tabuk Pharmaceuticals, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery CI
Mar. 07 Formosa Pharmaceuticals, Inc. Announces FDA Approval for the NDA of A Global Innovative Hormone Nanosuspension Eye Drops CI

Valuation

Fiscal Period: December 2021 2022 2023
Capitalization 1 3,390 5,921 6,700
Enterprise Value (EV) 1 3,184 5,507 5,514
P/E ratio -7.91 x -13.6 x -19.3 x
Yield - - -
Capitalization / Revenue 118,824,390 x 4,502,474,076 x 214,949,246 x
EV / Revenue 111,612,921 x 4,187,656,586 x 176,891,791 x
EV / EBITDA -9.22 x -16.1 x -22.3 x
EV / FCF -12,464,331 x -30,545,409 x 566,300,801 x
FCF Yield -0% -0% 0%
Price to Book 8.63 x 12 x 5.88 x
Nbr of stocks (in thousands) 98,832 113,642 134,142
Reference price 2 34.30 52.10 49.95
Announcement Date 3/16/22 3/21/23 2/26/24
1TWD in Million2TWD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales - 1.128 - 28.53 1.315 31.17
EBITDA 1 -167.8 -164.9 -200.6 -345.4 -341.2 -247.5
EBIT 1 -189.9 -198.7 -233.6 -380 -377.3 -283
Operating Margin - -17,618.88% - -1,332.01% -28,693.46% -907.98%
Earnings before Tax (EBT) 1 -242.6 -198.1 -220.2 -398.4 -402.2 -300.1
Net income 1 -172 -197.4 -219.7 -400.9 -401.9 -322
Net margin - -17,503.1% - -1,405.18% -30,564.41% -1,032.84%
EPS 2 -3.300 -3.044 -3.120 -4.334 -3.822 -2.595
Free Cash Flow - -184.5 -80.85 -255.5 -180.3 9.737
FCF margin - -16,358.8% - -895.46% -13,709.61% 31.24%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 5/4/21 5/4/21 5/4/21 3/16/22 3/21/23 2/26/24
1TWD in Million2TWD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 345 77.2 35.7 206 414 1,186
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow - -185 -80.9 -255 -180 9.74
ROE (net income / shareholders' equity) - -56.1% -97.6% -135% -90.6% -40%
ROA (Net income/ Total Assets) - -18.4% -29.5% -41.3% -30.1% -13.6%
Assets 1 - 1,075 745.6 971 1,335 2,370
Book Value Per Share 2 8.710 3.850 2.020 3.970 4.340 8.500
Cash Flow per Share 2 6.500 1.190 0.4200 2.110 2.350 2.870
Capex 1 3.52 0.24 4.66 0.22 - 2.17
Capex / Sales - 21.1% - 0.77% - 6.96%
Announcement Date 5/4/21 5/4/21 5/4/21 3/16/22 3/21/23 2/26/24
1TWD in Million2TWD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
FORMOSA PHARMACEUTICALS, INC. Stock Formosa Pharmaceuticals, Inc.
+6.71% 221M
NOVO NORDISK A/S Stock Novo Nordisk A/S
+31.37% 588B
JOHNSON & JOHNSON Stock Johnson & Johnson
-2.60% 364B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.83% 326B
ABBVIE INC. Stock AbbVie Inc.
+5.69% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.83% 239B
NOVARTIS AG Stock Novartis AG
+9.93% 210B
ROCHE HOLDING AG Stock Roche Holding AG
-6.95% 200B
AMGEN INC. Stock Amgen Inc.
+10.77% 167B
PFIZER, INC. Stock Pfizer, Inc.
+0.10% 161B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 6838 Stock
  4. Financials Formosa Pharmaceuticals, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW